AT-37 PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA

Although anti-angiogenic therapy for high-grade glioma is promising, responses are not durable. The SDF-1/CXCR4 axis may help mediate resistance to VEGFR inhibition. Plerixafor is a reversible CXCR4 inhibitor that has demonstrated growth inhibition in glioblastoma xenografts. We conducted a Phase I...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Lee, Eudocia, Smith, Katrina, Muzikansky, Alona, Gerstner, Elizabeth, Kuhn, John, Reardon, David, Nayak, Lakshmi, Norden, Andrew, Rifenburg, Jennifer, Pulverenti, Julee, Stokes, Deirdre, Lam, Priscilla, Martins, Tiago, Hempfling, Kelly, McCluskey, Christine, Gaffey, Sarah, Batchelor, Tracy, Duda, Dan, Jain, Rakesh, Wen, Patrick
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2014
נושאים:
Abstracts
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217816/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.37
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים